Core Insights - Gelteq Limited has announced preclinical findings that demonstrate the effectiveness, flexibility, and safety of its proprietary gel-based oral delivery systems, addressing significant challenges in pharmaceutical development [1][6]. Preclinical Study Results - Two preclinical studies showed a 300% increase in bioavailability of an oil-soluble compound in Gelteq's gel base compared to an existing FDA-approved reference product within the first hour, which is critical for rapid onset of action [2]. - Overall absorption of the oil-soluble compound improved by more than 20% over 24 hours when using Gelteq's gel base compared to the reference product [3]. - The gel platform enables controlled movement through the digestive system, targeted release, and effective absorption while ensuring full clearance of both the active pharmaceutical ingredients and the gel material [4]. Mechanism of Action - The gel disperses the active ingredient uniformly along the small intestine, enhancing absorption through mucoadhesive interactions and presenting the drug across a larger intestinal surface area [5]. - The gel's structural matrix allows for efficient transit and rapid early absorption of the active pharmaceutical ingredient, reinforcing its safety and compatibility with oral administration [6]. Industry Context - Over 40% of approved drugs and up to 90% of developmental candidates face issues with poor solubility and bioavailability, leading to significant annual investments in new technologies to address these challenges [7]. - Gelteq's platform offers a streamlined solution that may reduce developmental burdens, enhance bioavailability, and potentially revive previously shelved or challenging molecules [7]. Therapeutic Applications - Therapeutic areas likely to benefit from Gelteq's gel-based delivery system include neurology, inflammation and pain management, hormonal therapies, cardiovascular medicine, nutraceuticals, weight management, oncology, and veterinary health, where lipid-based or poorly soluble APIs are common [8]. Strategic Positioning - By enabling consistent absorption, targeted delivery, reduced reliance on excipients, and strong safety characteristics, Gelteq positions itself as a valuable development partner for pharmaceutical and nutraceutical companies looking to reformulate existing assets or tackle complex formulation challenges [9].
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform